Arca
Skip to content
Tools
Tools

Psoriatic arthritis

Drug research and approvals for psoriatic arthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 86 studies of psoriatic arthritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 49 drug trials for it since 2013, and the EU has 8 authorised medicines for it.

  • Recruiting worldwide: 86
  • Trials authorized in Canada: 49
  • FDA orphan approvals: 0
  • EU medicines: 8

Recruiting now

Newest posted first, of 86 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 19

Phase 3 7

Phase 2 12 of 16

Phase 1 or earlier 6

How its trials ended

525 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 168 whose ending is known, 70% met their primary endpoint, 4% missed it and 26% stopped early.

  • Completed, result not reported17734%
  • Ongoing14027%
  • Met its primary endpoint11822%
  • Status unknown408%
  • Stopped: other or unclear224%
  • Stopped: sponsor or business decision82%
  • Stopped: enrollment or feasibility71%
  • Missed its primary endpoint61%
  • Stopped: lack of efficacy51%
  • Stopped: funding2<1%

Trials authorized in Canada

The 10 newest of 49; search them all in Canada trials
Aug 11, 2026A randomized, double-blind, placebo-controlled, multicenter phase 2a/b study assessing the efficacy, safety and tolerability of DDY391 in participants with…DDY391Novartis PharmaceuticalsPending
May 13, 2026A phase 3, multicenter, long-term extension study to evaluate the long-term safety, tolerability, and efficacy of zasocitinib (TAK-279) in subjects with active…Zasocitinib (TAK-279)Takeda Pharmaceuticals USAPending
Apr 13, 2026A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with psoriatic arthritisTulisokibart (MK-7240)Merck & Co. (MSD)Ongoing
Apr 11, 2025A phase 2 multicenter, randomized, platform study of targeted therapies for the treatment of adult subjects with active psoriatic arthritisLutikizumab (ABT-981) / Risankizumab (ABBV-066)AbbVieOngoing
Mar 5, 2025A multi-center, randomized, double-blind, and placebo-controlled phase 3 study to evaluate the efficacy and safety of zasocitinib (TAK-279) in subjects with…Zasocitinib (TAK-279)Takeda Pharmaceuticals USAOngoing
Feb 7, 2025A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of JNJ-77242113 for the treatment of…Icotrokinra (JNJ-77242113)Johnson & JohnsonOngoing
Nov 20, 2024A phase 3, parallel-group, randomized, double-blind, 4-arm, placebocontrolled, multicenter study with risankizumab as active reference arm, to investigate the…SonelokimabMoonlake Immunotherapeutics AGOngoing
Nov 19, 2024A phase 3, parallel-group, randomized, double-blind, 3-arm, placebocontrolled, multicenter study to investigate the efficacy and safety of subcutaneous…SonelokimabMoonlake Immunotherapeutics AGOngoing
Sep 6, 2024A multicenter, randomized, double-blind, risankizumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult study…BimekizumabUCBClosed
Jul 19, 2024Open-label, single-arm trial to evaluate the pharmacokinetics and safety of bimekizumab in pediatric study participants from 2 to less than 18 years of age…BimekizumabUCBOngoing

Medicines authorised in the EU

Newest first
Apr 19, 2024Apremilast AccordApremilast · genericAccord Healthcare S.L.U.EMA ↗
Mar 24, 2023SotyktuDeucravacitinibBristol-Myers Squibb Pharma EEIGEMA ↗
Aug 20, 2021BimzelxBimekizumabUCB Pharma S.A.EMA ↗
May 18, 2018ZesslyInfliximab · biosimilarSandoz GmbHEMA ↗
Jan 15, 2015OtezlaApremilastAmgen Europe B.V.EMA ↗
Nov 28, 2010Leflunomide ratiopharmLeflunomide · genericRatiopharm GmbHEMA ↗
Jan 8, 2010Leflunomide Zentiva (previously Leflunomide Winthrop)LeflunomideZentiva k.s.EMA ↗
Sep 2, 1999AravaLeflunomideSanofi-aventis Deutschland GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.